AAIC 2025 Abstract
A Patient‐Centric, Digital Multimodal Post‐Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for Blarcamesine
Abstract
Background: There is a critical need to establish robust Real‐World Evidence (RWE) platform for monitoring both clinically relevant benefits and potential mid/long‐term side effects of Alzheimer’s disease (AD) drugs at an individual level, with the ambition to enhance personalized medicine in AD.
